Nuvalent (NUVL) Assets (2020 - 2026)
Nuvalent's (NUVL) quarterly Assets came in at $1.3 billion in Q1 2026, up 20.38% YoY from $1.1 billion in Q1 2025, and down 5.77% on a QoQ basis from $1.4 billion in Q4 2025.
Nuvalent (NUVL) Assets (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Assets data on file, last reported at $1.3 billion in Q1 2026.
- Quarterly Assets rose 20.38% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 20.38% YoY) and the FY2025 annual result came in at $1.4 billion, up 23.73% from the prior year.
- Assets eased to $1.3 billion in Q1 2026, from $1.4 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $1.4 billion in Q4 2025 to a low of $249.6 million in Q3 2022.
- A 5-year average of $759.8 million and a median of $708.5 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets dropped 18.97% — and 2024, when it jumped 179.68%.
- Tracing NUVL's Assets over 5 years: stood at $482.5 million in 2022, then surged by 51.8% to $732.4 million in 2023, then soared by 55.9% to $1.1 billion in 2024, then gained by 23.73% to $1.4 billion in 2025, then decreased by 5.77% to $1.3 billion in 2026.
- The last three Assets figures came in at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $979.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 1.33 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.33 Bn |
| Dec 31, 2025 | 1.41 Bn |
| Sep 30, 2025 | 979.91 Mn |
| Jun 30, 2025 | 1.04 Bn |
| Mar 31, 2025 | 1.11 Bn |
| Dec 31, 2024 | 1.14 Bn |
| Sep 30, 2024 | 1.19 Bn |
| Jun 30, 2024 | 675.23 Mn |
| Mar 31, 2024 | 708.47 Mn |
| Dec 31, 2023 | 732.38 Mn |
| Sep 30, 2023 | 425.08 Mn |
| Jun 30, 2023 | 441.95 Mn |
| Mar 31, 2023 | 460.99 Mn |
| Dec 31, 2022 | 482.46 Mn |
| Sep 30, 2022 | 249.56 Mn |
| Jun 30, 2022 | 263.02 Mn |
| Mar 31, 2022 | 277.04 Mn |
| Dec 31, 2021 | 293.82 Mn |
| Sep 30, 2021 | 307.97 Mn |
| Jun 30, 2021 | 143.50 Mn |